Publications
5166 Results
- Journal / Conference
- Prostate Cancer and Prostatic Diseases Feb 12. doi: 10.1038/s41391-022-00497-7
- Year
- 2022
- Research Committee(s)
- Cancer Control and Prevention and Epidemiology
- PMID
- PMID35152271
- Study Number(s)
- SWOG-9217
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
- Journal / Conference
- Lancet Oncology Feb;23(2):259-269
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35038433
- Study Number(s)
- CTSU/R1010
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
- Journal / Conference
- Journal of Geriatric Oncology Jan 29:S1879-4068(22)00007-8, 2022
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35105521
- Study Number(s)
- CTSU/C80405
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80702
Associations of Inflammatory Biomarkers with Survival Among Patients with Stage III Colon Cancer (CALGB/SWOG 80702 [Alliance])
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Immune Gene Expression Signatures associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial
- Journal / Conference
- American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), plenary, oral
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1616
SWOG S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy
- Journal / Conference
- ASCO Gastrointestinal Cancer Symposium (Jan 20-22, 2022, San Francisco, CA), poster session, Abst #193
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Circulating tumor DNA dynamics on front line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: a biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 6; abstr TPS194); ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA)
- Year
- 2022
- Research Committee(s)
- Genitourinary